本文利用基因重组技术获得的一种人GM-CSF与LIF融合蛋白rhGM-LIF,比较研究了不同浓度rhGM-LIF融合蛋白、rhGM-CSF与rhLIF单独使用及合用的体外抑瘤作用.结果表明,融合蛋白不但能够诱导髓系白血病细胞分化,而且能够抑制其生长,其抑制作用与用药剂量相关,在一定剂量范围内,这种作用显著地高于单个因子和两者合用的效果.值得重视的是,融合蛋白对人肝癌细胞的生长也有明显的抑制作用.实验结果提示,重组的融合蛋白具有潜在的抗肿瘤作用.

The recombinant human fusion protein GM-CSF/LIF was used to study the effects of different doses rhGM-LIF, rhGM-CSF,rhLIF,and rhGM-CSF plus rhLIF on tumor cells in our paper. The results showed that rhGM-LIF induced myeloid leukemia cells differentiation and inhibited the growth of the cells significantly. Its effect was dose-related, more significantly than rhGM-CSF,rhLIF,and rhGM-CSF plus rhLIF in some dose range. It is important that rhGM-LIF can inhibit the growth of human liver cancer cell. The rhGM-LIF might be a useful recombinant protein for tumor thera-py.